Aspirin and meloxicam (DrugBank: Meloxicam, Aspirin)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 49 | 全身性エリテマトーデス | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00731302 (ClinicalTrials.gov) | April 2005 | 5/8/2008 | Aspirin Resistance in Systemic Lupus Erythematosus (SLE) | Vascular Damage in Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | Drug: aspirin and meloxicam | Vanderbilt University | National Heart, Lung, and Blood Institute (NHLBI) | Completed | 18 Years | N/A | All | 70 | Phase 1 | United States |